Inovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial Nasdaq : globenewswire

referring to globenewswire

Inovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial Nasdaq

Inovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial Nasdaq

PLYMOUTH MEETING, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the dosing of the first subject in its multi-center phase I trial to evaluate Inovio's Zika DNA vaccine (GLS-5700).In addition to the previously announced US FDA approval for the conduct of the study, Health Canada's Health Products and Food Branch has also approved this study, which will be conducted at clinical sites in Miami, Philadelphia, and Quebec City.This phase I, open-label, dose-ranging study of 40 healthy adult volunteers is evaluating the safety, tolerability and immunogenicity of GLS-5700 administered with the CELLECTRA®-3P device, Inovio's proprietary intradermal DNA delivery device.


besides benzinga

GeneOne Life Science Doses First Subjects in Zika Vaccine Clinical Trial

GeneOne Life Science Doses First Subjects in Zika Vaccine Clinical Trial

GeneOne Life Science doses first subjects in a multi-center Phase I trial to evaluate the Zika DNA vaccine (GLS-5700).Seoul, Korea (PRWEB) July 26, 2016GeneOne Life Science, Inc. ("GeneOne" KOSPI: 011000) today announced the dosing of the first subjects in its multi-center Phase I trial to evaluate the Zika DNA vaccine (GLS-5700).Refer to ClinicalTrials.Gov, study number NCT02809443.


coupled with businesswire

FluGen Initiates a Phase 1 Clinical Trial of the RedeeFlu™ Universal Influenza Vaccine in Healthy Subjects

FluGen Initiates a Phase 1 Clinical Trial of the RedeeFlu™ Universal Influenza Vaccine in Healthy Subjects

MADISON, Wis.--(BUSINESS WIRE)--FluGen Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of more effective influenza vaccines, today announced the initiation of the first Phase 1 clinical trial of its RedeeFlu™ universal influenza vaccine.The trial is a randomized, blinded, dose-ranging Phase 1 study of the H3N2 RedeeFlu™ influenza vaccine in 96 healthy adult subjects between 18 and 49 years of age.In addition to the trial's primary goal of evaluating the safety of the vaccine in this population, the study also will evaluate both antibody and T-cell responses induced by the vaccine.